AGXT and metabolic dysfunction-associated steatohepatitis: Recent data suggest that “fatty liver” disease and nonalcoholic steatohepatitis (NASH) are associated with the hepatic down-regulation of AGXT, an enzyme whose activity reduces the generation of oxalate.